ABILIFY N: A Novel Treatment for Schizophrenia Schizophrenia is a chronic neurological disorder characterized by disturbances in thought and emotion, and an inability to recognize reality (Rosen & Seligman, 2017). To date, treatments for schizophrenia have been limited to antipsychotic medications. However, a new novel treatment option, ABILIFY N, has recently been developed and is […]
Reboxetine: A Selective Norepinephrine Reuptake Inhibitor Introduction and Core Definition Reboxetine is a pharmaceutical compound classified as a selective norepinephrine reuptake inhibitor (SNRI), primarily utilized in the management of certain psychiatric conditions. Its fundamental mechanism of action involves increasing the concentration of the neurotransmitter norepinephrine in the brain’s synaptic cleft, thereby enhancing its signaling effects. […]